Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cipher Pharmaceuticals has announced that the US Patent and Trademark Office has issued a patent notice of allowance for Cip-Isotretinoin, the company's novel formulation of the acne medication isotretinoin.
Subscribe to our email newsletter
The patent includes claims related to the reduced food effect of Cip-Isotretioin relative to currently marketed formulations, the company said.
Larry Andrews, president and CEO of Cipher, said: “Having the US patent allowed represents an important milestone on our path to commercialization for Cip-Isotretinoin. It also reinforces that the product is truly differentiated from currently marketed formulations.”